• Explore /
  • Poster
  • / Anti–PD-1 antibody (sintilimab) plus decitabine as first-line treatment for patients with higher-risk myelodysplastic syndrome (MDS): Preliminary results from a single-arm, open-label, phase II study.

Anti–PD-1 antibody (sintilimab) plus decitabine as first-line treatment for patients with higher-risk myelodysplastic syndrome (MDS): Preliminary results from a single-arm, open-label, phase II study.

Abstract Poster

Authors

null

Jing Wang

Peking University People’s Hospital, Peking University Institute of Hematology. National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation，Beijing, China., Beijing, China

Jing Wang , Siqi Li , Hao Jiang , Ying-Jun Chang , xiao-Su Zhao , jin-Song Jia , xiao-Lu Zhu , li-Zhong Gong , xiao-Hong Liu , wen-Jing Yu , xiao-Jun Huang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myelodysplastic Syndromes (MDS)

Clinical Trial Registration Number

ChiCTR2100044393

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7052)

DOI

10.1200/JCO.2022.40.16_suppl.7052

Abstract #

7052

Poster Bd #

283

Abstract Disclosures

Similar Posters

First Author: Jianqing Zhu

First Author: Jiafu Ji

First Author: Tony S. K. Mok

First Author: Philippe Armand